This review entails the overall comprehensive picture of the status of the upstream regulators and expressions of Cyclins and CDKs in the progression of gastric cancer, where many signaling axes have been implicated as direct therapeutic targets that can potentially lead to positive outcomes for patients in the future. Here, CCNL2 is linked to gastric cancer.